Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center pilot study is to determine if the drug tocilizumab
(Actemra) is effective in the treatment of patients with refractory adult polymyositis (PM)
and dermatomyositis (DM).